Rodjana Pongsararuk

Ms. Rodjana Pongsararuk


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Biosensors
Verified
Journal Article
Open access
PDF file
SSSukanya Saikaew
Sukanya Saikaew
Sirikwan SangboonruangSirikwan Sangboonruang
Sirikwan Sangboonruang
RPRodjana Pongsararuk
Rodjana Pongsararuk
PSPrapaporn Srilohasin
Prapaporn Srilohasin
BBBordin Butr-Indr
Bordin Butr-Indr
UWUsanee Wattananandkul
Usanee Wattananandkul
Tuberculosis (TB) remains a major global health challenge, particularly in resource-limited settings where access to rapid and reliable diagnostics is limited. Conventional diagnostic methods, such as smear microscopy and culture, are either time-consuming or lack adequate sensitivity. This study optimized recombinase polymerase amplification (RPA) using 16 primer combinations targeting IS6110 highly specific to the Mycobacterium tuberculosis complex (MTC). A novel naked-eye assay, TB-GoldDx, was developed by integrating RPA combined with gold nanoparticles (AuNPs), enabling equipment-free diagnostics. TB-GoldDx demonstrated a detection limit of 0.001 ng of MTB H37Rv DNA (~210 bacilli) per 25 µL reaction. Among 100 bacterial strains, it achieved 95.83% sensitivity and 100% specificity among 100 bacterial strains, comprising 72 MTB isolates and 28 nontuberculous bacterial species. In 140 sputum samples, the assay showed 81.43% sensitivity and 58.57% specificity versus acid-fast bacilli (AFB) smear microscopy, with sensitivity improving to 95.45% in high-load AFB 3+ specimens. Compared to a commercial line probe assay (LPA), TB-GoldDx exhibited slightly higher sensitivity (84.78% vs. 82.61%) but lower specificity (54.05% vs. 78.38%). Delivering rapid, visual results in under an hour, TB-GoldDx offers a low-cost, easily deployable solution for point-of-care tuberculosis detection, especially in underserved regions, reinforcing global End TB efforts.

10 September 2026 in Biosensors
Verified
Journal Article
Open access
PDF file
UWUsanee Wattananandkul
Usanee Wattananandkul
SSSukanya Saikaew
Sukanya Saikaew
Sirikwan SangboonruangSirikwan Sangboonruang
Sirikwan Sangboonruang
RPRodjana Pongsararuk
Rodjana Pongsararuk
PSPrapaporn Srilohasin
Prapaporn Srilohasin
Khajornsak TragoolpuaKhajornsak Tragoolpua
Khajornsak Tragoolpua
Drug-resistant tuberculosis remains a major challenge to tuberculosis control, particularly in settings with limited access to conventional molecular testing. This study developed and preliminarily evaluated RR-TB GoldDx and Hr-TB GoldDx, rapid visual assays for detecting rifampicin- and isoniazid-resistance-associated mutations in Mycobacterium tuberculosis. The assays combine recombinase polymerase amplification with unmodified gold nanoparticles (AuNPs) for amplification confirmation and thiol-probe-modified AuNPs for detecting resistance-associated mutations at rpoB codons 516, 526, and 531, katG codon 315, and position −15 of the fabG1–inhA promoter. Evaluation using DNA from 50 M. tuberculosis isolates yielded positive internal-control results for all samples. RR-TB GoldDx achieved accuracies of 84% and 86% against phenotypic drug-susceptibility testing and DNA sequencing, respectively, with Cohen’s kappa values of 0.68 and 0.72. Hr-TB GoldDx achieved 80% accuracy and a kappa value of 0.60 against phenotypic testing, while the inhA promoter and katG assays achieved sequencing-based accuracies of 84% and 86%, respectively. Results were available within 1 h at an estimated reagent cost of THB 500–550 (approximately USD 15–16) per test without conventional thermocycling, real-time fluorescence detection, or gel electrophoresis. These instrument-minimal assays show potential for rapid drug-resistance screening but require validation in larger, genetically diverse cohorts and direct respiratory specimens.